analysi sales/earn
turn point ipo ed limit estim
avail
one-year price volum histori
repotrectinib could class
increas pt
wednesday host financi corpor call despit
obviou covid overhang sever posit updat lead
clinic program repotrectinib solid tumor earli
stage pipelin walk note specif highlight
posit approv outlook repotrectinib evid pt increas
cash/cash equival market secur
book remain buy rate
fda track design grant repotrectinib tki-naiv
nsclc patient base phase portion studi
although mani second gener tki design overcom
gate-keep mutat follow tki treatment mani like
pfe-nc crizotinib roch rhhby-nc entretinib extra motif
render suscept solvent front mutat repotrectinib
therefor design prevent solvent front gate-keep mutat
surprisingli earli phase result tki-pretr patient
competit grant fda track design ftd
object respons rate orr tki-naiv patient also impress
mg qd analysi tki-naiv patient also suggest
repotrectinib response-dur could superior vs crizotinib
competit entrectinib repo vs ent month dor repo vs
ent month line yesterday announc ftd
also grant repotrectinib tki-naiv patient remind
indic approv drug exist one requir
ftd evid superior repotrectinib potenti superior
efficaci combin toler safeti profil becom
bullish approv outlook increas market penetr rate
probabl success accordingli price target previous
phase portion studi on-going impact
covid interim data updat still like phase
registr portion global trident studi appear progress
well vs site activ target enrol
patient independ dmc also recommend studi
continu compani also plan includ addit clinic site
particularli like idea site given note
delay trial site initi nevertheless manag believ
likelihood interim data includ physician-assess orr
patient registr exploratori cohort could provid
import disclosur regul ac certif locat page report
also expect interim data phase studi second clinic program
inhibitor tpx- inhibitor shown
in-vitro activ met-amplifi cell line rank one potent
inhibitor also first inhibitor novel macrocyl structur simultan target
kinas believ give strong competit advantag particularli
select inhibitor like capmatenib novarti nvs-nc tepotinib merck mrk-nc
also develop patient solid tumor harbor genet alter phase dose-
escal studi evalu safeti dosag pharmacokinet properti patient
advanc solid tumor dose-expans cohort includ treatment-nav pretreat nsclc
gastric/gej cancer patient mutat fusion studi continu enrol patient
interim data safeti earli efficaci still expect potenti show
differenti profil therefor believ recent approv novarti nvs-nc capmatinib could
pose limit competit instead valid select target addit novarti push
test like help identifi patient could amen treatment uniqu
lastli albeit near-term expect present preclin updat
ret/src inhibitor inhibitor repotrectinib combin asco virtual
meet later month plan present data test on-going phase
studi tki-naiv tki-pretr patient ret alter nsclc similar comment novarti
capmatinib believ lilli nc selpercatinib could also expand market
base seen repotrectinib date differenti product might import
time market manag also note call date enrol go well
aacr virtual meet june preclin updat inhibitor present
plan advanc toward ind submiss earli also preclin combin
data repotrectinib present posit outcom effort allow life-cycl
manag opportun develop combin lead even durabl respons
strategi explor key tki player believ updat although preclin
import investor
page
price target repotrectinib weight use probabl success
platform pipelin use probabl success net cash base dcf-npv-
sop analysi use discount rate growth rate factor could imped achiev
target price includ limit failur repotrectinib gain regulatori approv
smaller project commerci revenu repotrectinib due chang market size competit
landscap well reimburs challeng
clinic develop risk target tki space competit potenti enrol
occur slower pace project addit patient enrol current studi
efficaci safeti current observ could chang patient enrol chang
efficaci safeti profil could therefor affect recommend line use turn point tki
would materi
regulatori risk guarante fda approv repotrectinib pipelin asset therefor
drug candid includ valuat multipl reason could fail receiv fda approv
also possibl even approv approv timelin could vari project
commerci risk major development-stag biotechnolog compani commerci
prospect pipelin candid essenti present valuat current multipl competitor
turn point tki approv market penetr estim could vari
project also possibl market may abl toler price point use
model therefor revenu could come lower estim
financ risk major development-stag biotechnolog compani abil maintain
suffici fund critic progress pipelin commerci candid compani
experi problem rais suffici capit progress develop program could significantli
imped lead delay develop timelin well neg effect investor confid
could neg impact share price
turn inc clinical-stag biopharmaceut compani focus design
develop novel small molecul tyrosin kinas inhibitor tki use multipl oncolog indic
singl agent part combin strategi compani underli technolog platform
macrocycl platform potenti develop small compact potent atp-competit
inhibitor mimic size shape atp help prevent format solvent-front mutat
lead treatment resist compani lead clinic candid repotrectinib select tki
pivot phase studi interim result expect compani
also ret/src recent enter clinic
could also see earli result
page
incom statement million
good sold
research develop
gener administr
incom expens
compani sec file roth capit partner research
page
valuat million
add depreci amort
prob success
pv tv
pv tv
compani sec file roth capit partner research
page
ulat analyst certif ac research analyst primarili respons content report certifi
follow ac herebi certifi view express report accur reflect person view
subject compani compani secur also certifi part compens
directli indirectli relat specif recommend view express report
